Literature DB >> 32388625

The ASDEU autism prevalence study in northern Spain.

Joaquin Fuentes1,2, Ane Basurko3, Irma Isasa4, Isabel Galende5, María Dolores Muguerza6, Patricia García-Primo7, Jesús García8, Clara J Fernández-Álvarez9, Ricardo Canal-Bedia9, Manuel Posada de la Paz10.   

Abstract

The prevalence of autism spectrum disorders (ASD) was studied in children in the County of Gipuzkoa (Basque Country, Spain) as part of the European Union's Autism Spectrum Disorder in Europe project (ASDEU- https://asdeu.eu ). To identify cases in a total community sample of 7- to 9-year-old pupils (N = 14,734), a multistage approach was adopted: in the first stage, a teacher nomination (TN) form was completed by school teachers; and in the second stage, all families with a child nominated by their teachers were invited to complete the Social Communication Questionnaire (SCQ). A total of 108 (59%) schools participated fully, yielding a final sample of 9177 of 14.734 (61.9%) pupils. A total of 212 (2.3%) children were nominated via the TN form, and of these, 105 (49.5%) returned the completed SCQ. Twenty-five (23.8%) cases with SCQ scores ≥ 15 were invited to undergo a free clinical assessment, and 10 (40%) new cases of ASD were identified. The prevalence estimate included the 55 cases already being supported by the Gipuzkoa's only ASD association, the Gipuzkoa Autism Society (Asociación Guipuzcoana de Autismo/GAUTENA)), as well as the 10 new subjects identified by the ASDEU field diagnostic process. A sensitivity analysis was performed to estimate new potential ASD cases among the non-participant schools, leading to a final figure of 87 cases of ASD in this age-bracket at the date of the study. This global probabilistic estimate, including non-participating schools, would thus provide a population prevalence of 0.59% (95% CI 0.48-0.73), a result lower than those reported by some other studies. Attrition rates in cross-sectional studies are challenging and support the need for developing longitudinal ASD incidence surveillance study areas (ASD observatories).

Entities:  

Keywords:  ASD prevalence; ASDEU; Autism; Teacher nomination form

Year:  2020        PMID: 32388625     DOI: 10.1007/s00787-020-01539-y

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  5 in total

1.  A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.

Authors:  Christina Georgoula; Maite Ferrin; Bozena Pietraszczyk-Kedziora; Amaia Hervas; Stéphane Marret; Guiomar Oliveira; Antoine Rosier; Véronique Crutel; Emmanuelle Besse; Cristina Albarrán Severo; Denis Ravel; Joaquin Fuentes
Journal:  Child Psychiatry Hum Dev       Date:  2022-03-16

2.  Urinary metabolomics using gas chromatography-mass spectrometry: potential biomarkers for autism spectrum disorder.

Authors:  Zaib Un Nisa Khan; Prem Chand; Hafsa Majid; Sibtain Ahmed; Aysha Habib Khan; Azeema Jamil; Saba Ejaz; Ambreen Wasim; Khaleel Ahmad Khan; Lena Jafri
Journal:  BMC Neurol       Date:  2022-03-17       Impact factor: 2.474

3.  Evidence of increasing recorded diagnosis of autism spectrum disorders in Wales, UK: An e-cohort study.

Authors:  Jack Fg Underwood; Marcos DelPozo-Banos; Aura Frizzati; Ann John; Jeremy Hall
Journal:  Autism       Date:  2021-11-29

4.  The global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis.

Authors:  Nader Salari; Shabnam Rasoulpoor; Shna Rasoulpoor; Shamarina Shohaimi; Sima Jafarpour; Nasrin Abdoli; Behnam Khaledi-Paveh; Masoud Mohammadi
Journal:  Ital J Pediatr       Date:  2022-07-08       Impact factor: 3.288

5.  Serum Vitamin D, Folate and Fatty Acid Levels in Children with Autism Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Maria Carmen Gallardo-Carrasco; José Antonio Jiménez-Barbero; María Del Mar Bravo-Pastor; David Martin-Castillo; María Sánchez-Muñoz
Journal:  J Autism Dev Disord       Date:  2021-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.